AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30507022 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 876
Study 29301026 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal (active) cerebellar tDCS for 25 minutes
Number of subjects: 42
Study 29301026 — intervention group
Group type: COMPARATOR
Intervention: Sham cerebellar tDCS for 25 minutes
Number of subjects: 42
Study 26771947 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychotherapy (SET)
Number of subjects: 149
Study 26771947 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical management combined with pharmacotherapy (CM+MED)
Number of subjects: 149
Study 26771947 — intervention group
Group type: COMPARATOR
Intervention: Clinical management with placebo (CM+PBO)
Number of subjects: 149
Study 24091935 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM Level 1 (lowest activation)
Number of subjects: 695
Study 24091935 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM Level 2
Number of subjects: 695
Study 24091935 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM Level 3
Number of subjects: 695
Study 24091935 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM Level 1
Number of subjects: 695
Study 24091935 — intervention group
Group type: COMPARATOR
Intervention: PAM Level 4 (highest activation)
Number of subjects: 695
Study 22559139 — intervention group
Group type: EXPERIMENTAL
Intervention: High Vagal Regulatory Capacity (VRC) in a socially supportive context
Number of subjects: 61
Study 22559139 — intervention group
Group type: COMPARATOR
Intervention: High VRC in a nonsupportive context
Number of subjects: 61
Study 22559139 — intervention group
Group type: COMPARATOR
Intervention: Low VRC in either context
Number of subjects: 61
Study 20194388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique incremental technique (OIT) with Ceram X mono (CXM)
Number of subjects: 26
Study 20194388 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified incremental technique (MIT) with Ceram X mono (CXM) and SureFil (SF)
Number of subjects: 26
Study 20194388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique incremental technique (OIT) with SureFil (SF)
Number of subjects: 26
Study 17921064 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic CPAP (A‐CPAP)
Number of subjects: 45
Study 17921064 — intervention group
Group type: COMPARATOR
Intervention: Fixed CPAP (F‐CPAP)
Number of subjects: 45
Study 16207425 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with recombinant tissue‐type plasminogen activator (rtPA) intravenously
Number of subjects: 24
Study 16207425 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy with low molecular weight heparin
Number of subjects: 24
Study 12463459 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 12463459 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 0
Study 11910672 — intervention group
Group type: EXPERIMENTAL
Intervention: 40‐mg isoflavone supplement (one tablet per day)
Number of subjects: 51
Study 11910672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11910672 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined values for all subjects
Number of subjects: 51
Study 7722115 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (protocol 1)
Number of subjects: 29
Study 7722115 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (protocol 1)
Number of subjects: 29
Study 7722115 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (protocol 2)
Number of subjects: 29
Study 7722115 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (protocol 2)
Number of subjects: 29
Study 2039897 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder retraining and terodiline 25 mg daily
Number of subjects: 37
Study 2039897 — intervention group
Group type: COMPARATOR
Intervention: Bladder retraining and placebo
Number of subjects: 37
Study 31444003 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision ID Ancestry Panel (165 autosomal AIMs)
Number of subjects: 199
Study 31444003 — intervention group
Group type: EXPERIMENTAL
Intervention: GenoGeographer (new reference populations constructed from 75 Uyghur and 75 Kazakh individuals)
Number of subjects: 199
Study 31444003 — intervention group
Group type: EXPERIMENTAL
Intervention: GenoGeographer
Number of subjects: 199
Study 30040762 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual training with error augmentation
Number of subjects: 26
Study 30040762 — intervention group
Group type: COMPARATOR
Intervention: Bimanual training without error augmentation
Number of subjects: 26
Study 26578735 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 609
Study 26578735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 26578735 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 609
Study 24561653 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT 0.5 (1 HIT session every second week)
Number of subjects: 17
Study 24561653 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT 1 (1 HIT session per week)
Number of subjects: 17
Study 24561653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 17
Study 22332767 — intervention group
Group type: EXPERIMENTAL
Intervention: Spongiosum block along with intraurethral lignocaine
Number of subjects: 50
Study 22332767 — intervention group
Group type: COMPARATOR
Intervention: Intraurethral lignocaine only
Number of subjects: 50
Study 19846114 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided resistance training twice weekly for 4 months (team GCK)
Number of subjects: 46
Study 19846114 — intervention group
Group type: COMPARATOR
Intervention: Unchanged training schedules (team ZSC)
Number of subjects: 46
Study 19846114 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided resistance training (team GCK)
Number of subjects: 46
Study 17989121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond Plus Self Etching Primer (SEP), 3M Unitek
Number of subjects: 30
Study 17989121 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT, 3M Unitek
Number of subjects: 30
Study 15928801 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg/week
Number of subjects: 90
Study 15928801 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (one tab/week)
Number of subjects: 90
Study 12010205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 198
Study 10599727 — intervention group
Group type: COMPARATOR
Intervention: GH dosage group A, 4 IU/m2 day (approximately 0.045 mg/kg x day)
Number of subjects: 68
Study 10599727 — intervention group
Group type: EXPERIMENTAL
Intervention: GH dosage group B, first year 4 IU/m2 x day, thereafter 6 IU/m2 x day (approximately 0.0675 mg/kg/day)
Number of subjects: 68
Study 10599727 — intervention group
Group type: EXPERIMENTAL
Intervention: GH dosage group C, first year 4 IU/m2 x day, second year 6 IU/m2 x day, thereafter 8 IU/m2 x day (approximately 0.090 mg/kg x day)
Number of subjects: 68
Study 10599727 — intervention group
Group type: COMPARATOR
Intervention: GH dosage group A
Number of subjects: 68
Study 10599727 — intervention group
Group type: EXPERIMENTAL
Intervention: GH dosage group B
Number of subjects: 68
Study 10599727 — intervention group
Group type: EXPERIMENTAL
Intervention: GH dosage group C
Number of subjects: 68
Study 7774515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 or 5 mg/day
Number of subjects: 0
Study 7774515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 or 10 mg/day
Number of subjects: 0
Study 7774515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0
Study 7774515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril with diuretics (hydrochlorothiazide or piretanide)
Number of subjects: 0
Study 2043070 — intervention group
Group type: EXPERIMENTAL
Intervention: Plucking (51 eyes)
Number of subjects: 102
Study 2043070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding displacement (51 eyes)
Number of subjects: 102
Study 2043070 — intervention group
Group type: COMPARATOR
Intervention: Control (left eyes)
Number of subjects: 102
Study 6791226 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg d-amphetamine
Number of subjects: 45
Study 6791226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31167601 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) present on admission
Number of subjects: 686
Study 31167601 — intervention group
Group type: COMPARATOR
Intervention: Atrial fibrillation (AF) newly detected during hospital stay
Number of subjects: 686
Study 31167601 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 686
Study 31167601 — intervention group
Group type: COMPARATOR
Intervention: No atrial fibrillation (AF)
Number of subjects: 686
Study 27224980 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as usual)
Number of subjects: 321
Study 27224980 — intervention group
Group type: COMPARATOR
Intervention: TMC (TAU and telephone monitoring and counseling)
Number of subjects: 321
Study 27224980 — intervention group
Group type: COMPARATOR
Intervention: TMC+ (TAU and TMC plus incentives for participation in telephone contacts)
Number of subjects: 321
Study 26058405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-gel packing
Number of subjects: 70
Study 26058405 — intervention group
Group type: COMPARATOR
Intervention: Oral analgesics (control group)
Number of subjects: 70
Study 22882759 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of natural progesterone
Number of subjects: 290
Study 22882759 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of natural progesterone
Number of subjects: 290
Study 22882759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 21820536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) in a general fitness class (n=52)
Number of subjects: 105
Study 21820536 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group, n=53)
Number of subjects: 105
Study 19803419 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP/NT-proBNP-guided therapy
Number of subjects: 0
Study 19803419 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 0
Study 17557771 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SFC) 50 microg salmeterol and 500 microg fluticasone propionate twice daily for 3 months
Number of subjects: 60
Study 17557771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg twice daily for 3 months
Number of subjects: 60
Study 17557771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15098127 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric voluntary abduction of the shoulder joint
Number of subjects: 0
Study 15098127 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder joint abduction angle
Number of subjects: 0
Study 15098127 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked arm movement
Number of subjects: 0
Study 15098127 — intervention group
Group type: EXPERIMENTAL
Intervention: Forcible adduction of the arm
Number of subjects: 0
Study 11668653 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic interference (SI) effect trials with semantically-related distractors
Number of subjects: 0
Study 11668653 — intervention group
Group type: COMPARATOR
Intervention: Lexical control distractor conditions
Number of subjects: 0
Study 9651466 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice daily), clarithromycin (250 mg twice daily), and tinidazole or metronidazole (500 mg twice daily) for 1 week
Number of subjects: 35
Study 9651466 — intervention group
Group type: COMPARATOR
Intervention: Standard metronidazole and bismuth combination therapies
Number of subjects: 35
Study 7986443 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival irrigation with amine fluoride-stannous fluoride gel
Number of subjects: 8
Study 7986443 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 8
Study 2637081 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolved cisplatin (30 mg/24 hours)
Number of subjects: 133
Study 2637081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized cisplatin
Number of subjects: 133
Study 2637081 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatment with dissolved cisplatin (50 mg/die)
Number of subjects: 133
Study 2637081 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 133
Study 29952696 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback during bodyweight squats
Number of subjects: 20
Study 29952696 — intervention group
Group type: COMPARATOR
Intervention: Control (sham) feedback during bodyweight squats
Number of subjects: 20
Study 28595250 — intervention group
Group type: EXPERIMENTAL
Intervention: ART FILLER Universal (AFU)
Number of subjects: 61
Study 28595250 — intervention group
Group type: EXPERIMENTAL
Intervention: ART FILLER Fine lines (AFFL)
Number of subjects: 61
Study 28595250 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Aesthetic Improvement Scale (GAIS)
Number of subjects: 61
Study 28595250 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen synthesis
Number of subjects: 61
Study 25919966 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 28
Study 25919966 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg)
Number of subjects: 28
Study 25919966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both aspirin and celecoxib)
Number of subjects: 28
Study 23036841 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer package group
Number of subjects: 21
Study 23036841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 21306414 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 44
Study 21306414 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 100 mg
Number of subjects: 44
Study 21306414 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 44
Study 21306414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19673817 — intervention group
Group type: EXPERIMENTAL
Intervention: Receptive music therapy programs
Number of subjects: 150
Study 19673817 — intervention group
Group type: COMPARATOR
Intervention: Placebo and waiting-list control groups
Number of subjects: 150
Study 16495394 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (6, 14, or 30 mg every three months or 14, 60, 100, or 210 mg every six months)
Number of subjects: 412
Study 16495394 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (70 mg once weekly)
Number of subjects: 412
Study 16495394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 15525311 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bupivacaine (0.25%)
Number of subjects: 135
Study 15525311 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 135
Study 11396195 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose oxidase-Schiff test
Number of subjects: 137
Study 11396195 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals free of malignancies)
Number of subjects: 137
Study 9629990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordaflex 20 mg retard filmtablet after fasting
Number of subjects: 12
Study 9629990 — intervention group
Group type: COMPARATOR
Intervention: Cordaflex 20 mg retard filmtablet after food ingestion
Number of subjects: 12
Study 7917771 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 10
Study 2901784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine or famotidine for 4-8 weeks
Number of subjects: 65
Study 2901784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine or famotidine
Number of subjects: 65
Study 29164649 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group
Number of subjects: 108
Study 29164649 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking group
Number of subjects: 108
Study 29164649 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-smoking group
Number of subjects: 108
Study 29164649 — intervention group
Group type: COMPARATOR
Intervention: Control (nonalcoholic and nonsmoker patients)
Number of subjects: 108
Study 27155968 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted activity (AAA) with a dog, 30 min sessions, twice a week for 12 weeks
Number of subjects: 80
Study 27155968 — intervention group
Group type: COMPARATOR
Intervention: Control group with treatment as usual
Number of subjects: 80
Study 27155968 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted activity (AAA) with a dog
Number of subjects: 80
Study 26229963 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 116
Study 26229963 — intervention group
Group type: COMPARATOR
Intervention: Phenprocoumon
Number of subjects: 116
Study 24148575 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV‐NG
Number of subjects: 816
Study 24148575 — intervention group
Group type: COMPARATOR
Intervention: Verorab
Number of subjects: 816
Study 21050644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of bovine bone mineral (BBM) and autogenous cortical bone scrapings (1:4)
Number of subjects: 24
Study 21050644 — intervention group
Group type: COMPARATOR
Intervention: Bovine bone mineral (BBM) alone
Number of subjects: 24
Study 18507840 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits by non-physician health professionals (geriatric assessment, consultation, booster session)
Number of subjects: 320
Study 18507840 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study 16555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 48
Study 16555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 48
Study 16555061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 14517494 — intervention group
Group type: EXPERIMENTAL
Intervention: Melagatran 0.1-5 mg single subcutaneous doses
Number of subjects: 0
Study 14517494 — intervention group
Group type: EXPERIMENTAL
Intervention: Melagatran 3 mg subcutaneous doses every 12 hours for 4 days
Number of subjects: 0
Study 10624638 — intervention group
Group type: EXPERIMENTAL
Intervention: IV PCA with morphine
Number of subjects: 1338
Study 10624638 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous '3-in-1' block
Number of subjects: 1338
Study 10624638 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 1338
Study 9183421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 33
Study 9183421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with fentanyl 50 micrograms
Number of subjects: 33
Study 9183421 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 33
Study 2192374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone-inhibiting dynamic ankle-foot orthosis (TIAFO)
Number of subjects: 1
Study 2192374 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated plastic molded ankle-foot orthosis (AFO)
Number of subjects: 1
Study 2192374 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 1
Study 343913 — intervention group
Group type: EXPERIMENTAL
Intervention: 2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl 1-methoxycyclopentyl ether (mepitiostane) 10 mg b.i.d.
Number of subjects: 50
Study 343913 — intervention group
Group type: COMPARATOR
Intervention: Fluoxymesterone 10 mg b.i.d. (Control)
Number of subjects: 50
Study 28351743 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with load (5% of body weight on non-paretic ankle)
Number of subjects: 38
Study 28351743 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training without load (control group)
Number of subjects: 38
Study 27259311 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (50 μg/min)
Number of subjects: 60
Study 27259311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (4 mg/min)
Number of subjects: 60
Study 24362908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy using frozen gel gloves
Number of subjects: 53
Study 24362908 — intervention group
Group type: COMPARATOR
Intervention: Control (non-gloved hand)
Number of subjects: 53
Study 22650317 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel (5 mg applied topically three times daily for 3 months)
Number of subjects: 20
Study 22650317 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant capsules (twice daily for 3 months)
Number of subjects: 20
Study 19250006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger 250 mg capsules for 4 days
Number of subjects: 67
Study 19250006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 17762964 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD‐SCAN
Number of subjects: 74
Study 17762964 — intervention group
Group type: EXPERIMENTAL
Intervention: PhiCal‐Test
Number of subjects: 74
Study 17762964 — intervention group
Group type: EXPERIMENTAL
Intervention: LEUKO‐TEST
Number of subjects: 74
Study 17762964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexagon OBTI
Number of subjects: 74
Study 17762964 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐reactive protein
Number of subjects: 74
Study 17762964 — intervention group
Group type: EXPERIMENTAL
Intervention: blood leukocytes
Number of subjects: 74
Study 17762964 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin and lactoferrin
Number of subjects: 74
Study 17762964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal sampling feasibility
Number of subjects: 74
Study 15726523 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily subcutaneous injection of amifostine
Number of subjects: 0
Study 15726523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus infusions of amifostine
Number of subjects: 0
Study 15726523 — intervention group
Group type: COMPARATOR
Intervention: Standard (once-daily) radiation therapy alone
Number of subjects: 0